Barclays PLC Increases Holdings in AngioDynamics, Inc. (NASDAQ:ANGO)

Barclays PLC boosted its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 81.0% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 83,582 shares of the medical instruments supplier's stock after purchasing an additional 37,394 shares during the period. Barclays PLC owned about 0.21% of AngioDynamics worth $651,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Quarry LP lifted its position in shares of AngioDynamics by 75.1% during the 2nd quarter. Quarry LP now owns 6,047 shares of the medical instruments supplier's stock valued at $37,000 after buying an additional 2,594 shares in the last quarter. CWM LLC raised its stake in AngioDynamics by 981.3% during the 3rd quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier's stock worth $76,000 after acquiring an additional 8,832 shares during the period. Mackenzie Financial Corp purchased a new position in AngioDynamics during the second quarter valued at approximately $80,000. Wealth Enhancement Advisory Services LLC bought a new position in shares of AngioDynamics in the third quarter worth approximately $86,000. Finally, AE Wealth Management LLC purchased a new stake in shares of AngioDynamics in the second quarter worth $87,000. Institutional investors own 89.43% of the company's stock.

Insider Activity at AngioDynamics

In other news, SVP Warren Nighan, Jr. sold 4,060 shares of the company's stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $12.31, for a total transaction of $49,978.60. Following the sale, the senior vice president now directly owns 41,817 shares of the company's stock, valued at $514,767.27. This represents a 8.85 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 5.40% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on ANGO. HC Wainwright lifted their target price on shares of AngioDynamics from $14.00 to $15.00 and gave the company a "buy" rating in a research note on Friday, January 10th. Canaccord Genuity Group lowered their price objective on AngioDynamics from $13.00 to $12.00 and set a "buy" rating on the stock in a research report on Friday, October 4th.

AngioDynamics Stock Performance

Shares of AngioDynamics stock traded down $0.34 on Friday, hitting $12.43. 551,568 shares of the company traded hands, compared to its average volume of 1,233,170. AngioDynamics, Inc. has a 52 week low of $5.26 and a 52 week high of $13.13. The business has a 50-day simple moving average of $8.75 and a 200 day simple moving average of $7.65. The stock has a market capitalization of $503.04 million, a P/E ratio of -2.21 and a beta of 0.59.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its quarterly earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.07. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The business had revenue of $72.90 million for the quarter, compared to analysts' expectations of $70.93 million. During the same quarter in the previous year, the company earned ($0.05) EPS. The business's quarterly revenue was down .1% compared to the same quarter last year. Research analysts expect that AngioDynamics, Inc. will post -0.36 earnings per share for the current year.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.